Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia

Thorax

Volumn 64, Issue 7, 2009, Pages 592-597

  Chalmers, J D ^a   Singanayagam, A ^a   Murray, M P ^a   Scally, C ^a   Fawzi, A ^a   Hill, A T ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; SODIUM; UREA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALCOHOL ABUSE; APACHE; AREA UNDER THE CURVE; ARTICLE; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMPLICATED PARAPNEUMONIC EFFUSION; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG USE; EMPYEMA; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NATIONAL HEALTH SERVICE; OBSERVATIONAL STUDY; PLEURA EFFUSION; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPSIS; SODIUM BLOOD LEVEL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; UNITED KINGDOM; UREA BLOOD LEVEL;

EID: 67650239640     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.105080     Document Type: Article

References (32)

1. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest 1978;74:170-3.
2. Davies CWH, Gleeson FV, Davies RJO. BTS guidelines for the management of pleural infection. Thorax 2003;58(Suppl 2):ii18-28.
3. Davies CW, Kearney SE, Gleeson FV, et al. Predictors of outcome and long term survival in patients with pleural infection. Am J Respir Crit Care Med 1999;160:1682-7.
4. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med 1980;69:507-12.
5. Lim WS, Van Der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
6. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8.
7. Fine MJ, Auble TE, Yealy DM, et al. Prediction rule to identify low risk patients with community acquired pneumonia. N Engl J Med 1997;336:243-50.
8. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006;27:151-7.
9. Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax 2008;63:698-702.
10. Knaus WA, Draper EA, Wagner DP, et al. Apache II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
11. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55.
12. Subbe CP, Kruger M, Rutherford P, et al. Validation of a modified early warning score in medical admissions. QJM 2001;94:521-6.
13. Allison PD. Logistic regression using the SAS system. Cary, NC: SAS Institute, 1999
14. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operator characteristic curves: a nonparametric approach. Biometrics 1998;44:837-45.
15. LeMense GP, Strange C, Sahn SA. Empyema thoracis: therapeutic management and outcome. Chest 1995;107:1532-7.
16. Alfagame I, Munoz F, Pena N, et al. Empyema of the thorax in adults: etiology, microbiologic findings and management. Chest 1993;103:839-43.
17. Chung CL, Chen CH, Sheu JR, et al. Proinflammatory cytokines, transforming growth factor-beta1 and fibrinolytic enzymes in loculated and free flowing pleural exudates. Chest 2005;128:690-7.
18. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent marker of severity in community acquired pneumonia. Am J Med 2008;121:219-25.
19. Hansson LO, Hedlund JU, Ortqvist AB. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest 1997;57:111-8.
20. Icard P, Fleury JP, Regnard JF, et al. Utility of C-reactive protein measurements for empyema diagnosis after pneumonectomy. Ann Thorac Surg 1994;57:933-6.
21. Klinger MH, Jelkmann W. Role of blood platelets in inflammation and infection. J Interferon Cytokine Res 2002;22:913-22.
22. Petty BG, Smith CR. The syndrome of inappropriate secretion of antidiuretic hormone associated with anaerobic thoracic empyema. Am Rev Respir Dis 1977;115:685-8.
23. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-41.
24. Cham CW, Haq SM, Rahamim J. Empyema thoracis: a problem with late referral? Thorax 1993;48:925-7.
25. Torres A, Menendez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur Respir J 2006;28:262-3.
26. Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999;14:218-20.
27. Maskell NA, Davies CW, Nunn AJ, et al. UK controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74.
28. Ahmed R, Marrie TJ, Huang JQ. Thoracic empyema in patients with community acquired pneumonia. Am J Med 2006;119:877-83
29. Bouros D, Schiza S, Tzanakis N, et al. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. a randomized, double-blind study. Am J Respir Crit Care Med 1999;159:37-42
30. Davies CW, Kearney SE, Gleeson FV, et al. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999;160:1682-7.
31. Chin NK, Lim TK. Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions. Chest 1997;111:275-9
32. Lindstrom ST, Kolbe J. Community acquired parapneumonic thoracic empyema: predictors of outcome. Respirology 1999;4:173-9